No Data
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround
Piper Sandler Maintains CytomX(CTMX.US) With Buy Rating, Cuts Target Price to $3.25
CytomX Therapeutics Price Target Lowered to $3.25 From $3.50 at Piper Sandler
CytomX Therapeutics, Inc. (CTMX) Q3 2024 Earnings Call Transcript Summary
12 Health Care Stocks Moving In Friday's Pre-Market Session